liu.seSearch for publications in DiVA
Change search
ReferencesLink to record
Permanent link

Direct link
Do pharmacokinetic polymorphisms explain treatment failure in high-risk patients with neuroblastoma?
Division of Pharmacology, Leiden/Amsterdam Centre Drug Research, Leiden, The Netherlands.
Linköping University, Department of Clinical and Experimental Medicine, Clinical Chemistry. Linköping University, Faculty of Health Sciences. Östergötlands Läns Landsting, Center for Diagnostics, Department of Clinical Chemistry.
Division of Pharmacology, Leiden/Amsterdam Centre Drug Research, Leiden, The Netherlands.
2011 (English)In: EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, ISSN 0031-6970, Vol. 67, S87-S107 p.Article, review/survey (Refereed) Published
Abstract [en]

Purpose Neuroblastoma is the most common extracranial solid tumour in childhood. It accounts for 15% of all paediatric oncology deaths. In the last few decades, improvement in treatment outcome for high-risk patients has not occurred, with an overall survival rate andlt;30-40%. Many reasons may account for such a low survival rate. The aim of this review is to evaluate whether pharmacogenetic factors can explain treatment failure in neuroblastoma. Methods A literature search based on PubMeds database Medical Subject Headings (MeSH) was performed to retrieve all pertinent publications on current treatment options and new classes of drugs under investigation. One hundred and fifty-eight articles wer reviewed, and relevant data were extracted and summarised. Results and conclusions Few of the large number of polymorphisms identified thus far showed an effect on pharmacokinetics that could be considered clinically relevant. Despite their clinical relevance, none of the single nucleotide polymorphisms (SNPs) investigated can explain treatment failure. These findings seem to reflect the clinical context in which anti-tumour drugs are used, i.e. in combination with multi-modal therapy. In addition, many pharmacogenetic studies did not assess (differences in) drug exposure, which could contribute to explaining pharmacogenctic associations. Furthermore, it remains unclear whether the significant activity of new drugs on different neuroblastoma cell lines translates into clinical efficacy, irrespective of resistance or myelocytomatosis viral related oncogene, neuroblastoma derived (MYCN) amplification. Elucidation of the clinical role of pharmacogenetic factors in the treatment of neuroblastoma demands an integrated pharmacokinetic pharmacodynamic approach to the analysis of treatment response data.

Place, publisher, year, edition, pages
Springer Science Business Media , 2011. Vol. 67, S87-S107 p.
Keyword [en]
Neuroblastoma, Pharmacogenetics, Pharmacokinetics, Cytotoxic drugs, Modelling andamp, simulation, PKPD modelling
National Category
Medical and Health Sciences
URN: urn:nbn:se:liu:diva-68823DOI: 10.1007/s00228-010-0966-3ISI: 000290738000011OAI: diva2:421227
Available from: 2011-06-08 Created: 2011-06-08 Last updated: 2014-10-22

Open Access in DiVA

No full text

Other links

Publisher's full text

Search in DiVA

By author/editor
Kågedal, Bertil
By organisation
Clinical ChemistryFaculty of Health SciencesDepartment of Clinical Chemistry
Medical and Health Sciences

Search outside of DiVA

GoogleGoogle Scholar
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

Altmetric score

Total: 40 hits
ReferencesLink to record
Permanent link

Direct link